- I2PURE Chemistry
- The Science
- Product Pipeline
- Documentation -
- BioTech vs Microbes
- The Power of Science
- Completed Science
- Dr. Kessler Published Manuscripts -
- SEP 2022 - Journal of Infectious Diseases & Therapy
- 02/03/22 - Journal of Hospital Infection
- J. Pharm. Pharmacol
- Journal of Hospital Infection
- The Breast Journal
- Thyroid
- Thyroid
- International Journal of Pharmaceutics
- The Journal of Biological Chemistry
- 3rd Party Test Results -
- Request the Cytotoxicity Study
- Request the ASTM E2315 Bacteria Panel Report
- Request the ASTM E2755 Persistence Report
- Request the SARS CoV-2 Report
- Blog
- News
- Company Info
About Us
Many years of research, led by Dr. Jack Kessler, have resulted in a major breakthrough in iodine chemistry. Dr. Kessler has developed a unique and stable formulation of free molecular iodine (I2) that enables it to be highly concentrated as an ingredient in a variety of mediums. This higher concentration of free iodine increases the native virucidal activity of I2 to kill bacteria, viruses and fungi. The antimicrobial activity is proportional to the concentration of the free iodine (I2) released 5.
When applied to the skin, the free molecular iodine (I2) is absorbed directly into the dermis. It cannot be washed away 4 .
Our Leadership Team
Dr. Jack Kessler - Chief Science Officer
The I2PURE formulations come from a long line of revolutionary inventions by Dr. Jack Kessler. Dr. Kessler’s academic journey began at Steven’s Institute of Technology where he obtained his Bachelor of Science. He later went on achieve his Ph.D. in Chemistry from the State University of New York, Syracuse.
Dr. Jack Kessler has worked as Senior Scientist, New Technology Evaluation at Hoffman-LaRoche, a Swiss multinational healthcare company. He later went on to work as Senior Principal Systems Engineer at Elbit Systems of America. He is a member of the founding team of Symbollon Pharmaceuticals, Iotech International and I2PURE, all three of which are focused on the development and commercialization of proprietary drugs based on molecular iodine technology.
He has led formulation teams responsible for the development of several iodine-based products including the Violet tablet, ioRinse line of oral care products and the initial generation (powder) of the Iodozyme teat dip product marketed by DeLaval. He has also published basic and applied research on iodine formulations and the biochemistry of iodine/thyroid hormones.
Dr. Kessler’s list of inventions includes a molecular iodine-based solid oral dosage for mammary dysplasia and methods, systems, and devices to identify microorganisms in culture samples. Dr. Kessler has dedicated more than 25 years to the development of applicative areas of iodine-based formulations, bio-analytical assays, and in vitro diagnostic (IVD) medical devices.
Dr. Jack Kessler’s patents have been filed for approval at the United States Patent and Trademark Office (USPTO). His patent listings include applications pending approval as well as patents already granted by the USPTO.
